156 related articles for article (PubMed ID: 38164129)
21. Pancreatic islet autoimmunity.
Boitard C
Presse Med; 2012 Dec; 41(12 P 2):e636-50. PubMed ID: 23182678
[TBL] [Abstract][Full Text] [Related]
22. A multi-epitope DNA vaccine enables a broad engagement of diabetogenic T cells for tolerance in Type 1 diabetes.
Postigo-Fernandez J; Creusot RJ
J Autoimmun; 2019 Mar; 98():13-23. PubMed ID: 30454875
[TBL] [Abstract][Full Text] [Related]
23. Immune Cell Plasticity Allows for Resetting of Phenotype From Effector to Regulator With Combined Inhibition of Notch/eIF5A Pathways.
Imam S; Dar P; Aziz SW; Zahid ZA; Sarwar H; Karim T; Faisal S; Haseeb I; Naqvi AS; Shah R; Haque A; Salim N; Jaume JC
Front Cell Dev Biol; 2021; 9():777805. PubMed ID: 34881246
[TBL] [Abstract][Full Text] [Related]
24. Development of a Bioconjugate Platform for Modifying the Immune Response of Autoreactive Cytotoxic T Lymphocytes Involved in Type 1 Diabetes.
Nandedkar-Kulkarni N; Vartak AR; Sucheck SJ; Wall KA; Quinn A; Morran MP; McInerney MF
Bioconjug Chem; 2019 Jul; 30(7):2049-2059. PubMed ID: 31274300
[TBL] [Abstract][Full Text] [Related]
25. Transfusion of apoptotic beta-cells induces immune tolerance to beta-cell antigens and prevents type 1 diabetes in NOD mice.
Xia CQ; Peng R; Qiu Y; Annamalai M; Gordon D; Clare-Salzler MJ
Diabetes; 2007 Aug; 56(8):2116-23. PubMed ID: 17496235
[TBL] [Abstract][Full Text] [Related]
26. Tetrahedral Framework Nucleic Acids Induce Immune Tolerance and Prevent the Onset of Type 1 Diabetes.
Gao S; Li Y; Xiao D; Zhou M; Cai X; Lin Y
Nano Lett; 2021 May; 21(10):4437-4446. PubMed ID: 33955221
[TBL] [Abstract][Full Text] [Related]
27. Artesunate prevents type 1 diabetes in NOD mice mainly by inducing protective IL-4-producing T cells and regulatory T cells.
Li Z; Shi X; Liu J; Shao F; Huang G; Zhou Z; Zheng P
FASEB J; 2019 Jul; 33(7):8241-8248. PubMed ID: 30916998
[TBL] [Abstract][Full Text] [Related]
28. Administration of recombinant human thioredoxin-1 significantly delays and prevents autoimmune diabetes in nonobese diabetic mice through modulation of autoimmunity.
Chernatynskaya AV; Looney B; Hu H; Zhu X; Xia CQ
Diabetes Metab Res Rev; 2011 Nov; 27(8):809-12. PubMed ID: 22069264
[TBL] [Abstract][Full Text] [Related]
29. Toward testing the hypothesis that group B coxsackieviruses (CVB) trigger insulin-dependent diabetes: inoculating nonobese diabetic mice with CVB markedly lowers diabetes incidence.
Tracy S; Drescher KM; Chapman NM; Kim KS; Carson SD; Pirruccello S; Lane PH; Romero JR; Leser JS
J Virol; 2002 Dec; 76(23):12097-111. PubMed ID: 12414951
[TBL] [Abstract][Full Text] [Related]
30. Combination Therapy Using IL-2/IL-2 Monoclonal Antibody Complexes, Rapamycin, and Islet Autoantigen Peptides Increases Regulatory T Cell Frequency and Protects against Spontaneous and Induced Type 1 Diabetes in Nonobese Diabetic Mice.
Manirarora JN; Wei CH
J Immunol; 2015 Dec; 195(11):5203-14. PubMed ID: 26482409
[TBL] [Abstract][Full Text] [Related]
31. The tyrphostin agent AG490 prevents and reverses type 1 diabetes in NOD mice.
Davoodi-Semiromi A; Wasserfall CH; Xia CQ; Cooper-DeHoff RM; Wabitsch M; Clare-Salzler M; Atkinson M
PLoS One; 2012; 7(5):e36079. PubMed ID: 22615750
[TBL] [Abstract][Full Text] [Related]
32. Preclinical Models to Evaluate the Human Response to Autoantigen and Antigen-Specific Immunotherapy in Human Type 1 Diabetes.
Houeiss P; Boitard C; Luce S
Front Endocrinol (Lausanne); 2022; 13():883000. PubMed ID: 35498419
[TBL] [Abstract][Full Text] [Related]
33. Adoptive transfer of immunomodulatory M2 macrophages prevents type 1 diabetes in NOD mice.
Parsa R; Andresen P; Gillett A; Mia S; Zhang XM; Mayans S; Holmberg D; Harris RA
Diabetes; 2012 Nov; 61(11):2881-92. PubMed ID: 22745325
[TBL] [Abstract][Full Text] [Related]
34. Bridging Mice to Men: Using HLA Transgenic Mice to Enhance the Future Prediction and Prevention of Autoimmune Type 1 Diabetes in Humans.
Serreze DV; Niens M; Kulik J; DiLorenzo TP
Methods Mol Biol; 2016; 1438():137-51. PubMed ID: 27150089
[TBL] [Abstract][Full Text] [Related]
35. Prevention or early cure of type 1 diabetes by intranasal administration of gliadin in NOD mice.
Funda DP; Fundova P; Hansen AK; Buschard K
PLoS One; 2014; 9(4):e94530. PubMed ID: 24728138
[TBL] [Abstract][Full Text] [Related]
36. Dose-dependent bioavailability and tissue distribution of the ATR inhibitor AZD6738 (ceralasertib) in mice.
Kiesel BF; Guo J; Parise RA; Venkataramanan R; Clump DA; Bakkenist CJ; Beumer JH
Cancer Chemother Pharmacol; 2022 Feb; 89(2):231-242. PubMed ID: 35066692
[TBL] [Abstract][Full Text] [Related]
37. Genetic and functional data identifying Cd101 as a type 1 diabetes (T1D) susceptibility gene in nonobese diabetic (NOD) mice.
Mattner J; Mohammed JP; Fusakio ME; Giessler C; Hackstein CP; Opoka R; Wrage M; Schey R; Clark J; Fraser HI; Rainbow DB; Wicker LS
PLoS Genet; 2019 Jun; 15(6):e1008178. PubMed ID: 31199784
[TBL] [Abstract][Full Text] [Related]
38. Exposure to DDT metabolite p,p'-DDE increases autoimmune type 1 diabetes incidence in NOD mouse model.
Cetkovic-Cvrlje M; Olson M; Schindler B; Gong HK
J Immunotoxicol; 2016; 13(1):108-18. PubMed ID: 25721050
[TBL] [Abstract][Full Text] [Related]
39. Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei.
Dillon MT; Barker HE; Pedersen M; Hafsi H; Bhide SA; Newbold KL; Nutting CM; McLaughlin M; Harrington KJ
Mol Cancer Ther; 2017 Jan; 16(1):25-34. PubMed ID: 28062704
[TBL] [Abstract][Full Text] [Related]
40. Serological Proteome Analysis (SERPA) as a tool for the identification of new candidate autoantigens in type 1 diabetes.
Massa O; Alessio M; Russo L; Nardo G; Bonetto V; Bertuzzi F; Paladini A; Iafusco D; Patera P; Federici G; Not T; Tiberti C; Bonfanti R; Barbetti F
J Proteomics; 2013 Apr; 82():263-73. PubMed ID: 23500132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
